SEER Database Analysis Services for Cancer Epidemiology and Survival Research

SEER (Surveillance, Epidemiology, and End Results) analysis is a powerful population-based research approach that enables investigators to explore cancer incidence, treatment patterns, and survival outcomes across millions of patient records. Our professional SEER experimental analysis service provides end-to-end support, from data extraction and cohort construction to advanced statistical modeling and publication-ready visualization. With rigorous methodological standards and experienced biostatisticians, we help researchers transform public registry data into high-impact oncology publications.

Technical Overview

The Surveillance, Epidemiology, and End Results (SEER) program, maintained by the National Cancer Institute (NCI) of the United States, is one of the most authoritative population-based cancer registries in the world. Since 1973, SEER has continuously collected clinical and demographic information on cancer patients from population-based registries covering approximately 48% of the US population. The database records patient demographics, primary tumor site, tumor morphology, histologic grade, stage at diagnosis, first-course treatment, follow-up survival time, and cause of death, making it an invaluable resource for retrospective oncology research.

SEER experimental analysis refers to the systematic process of extracting, cleaning, and statistically modeling SEER data to answer specific clinical and epidemiological questions. Because the dataset is publicly available, de-identified, and continuously updated, it has become a cornerstone for clinical prediction model development, cancer epidemiology studies, and health services research. Our analysis services follow a standardized workflow: research question definition, cohort screening using ICD-O-3 histology and site codes, variable recoding and quality control, statistical analysis, and interpretation of results in a clinically meaningful framework.

Analysis Samples

SEER analysis can be applied to virtually all malignancies recorded in the registry. Based on common publication trends and client research needs, we routinely support the following categories of study cohorts:

Common Solid Tumors

Cohorts for high-incidence malignancies such as breast cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, hepatocellular carcinoma, gastric cancer, and pancreatic cancer. Large sample sizes in these cohorts enable subgroup analyses, propensity score matching, and the construction of high-precision prognostic models.

Rare Malignancies

For uncommon tumors such as adrenocortical carcinoma, cholangiocarcinoma, anal melanoma, thymic carcinoma, and sarcoma subtypes, SEER provides one of the few data sources with sufficient case numbers for meaningful statistical inference. Rare disease analysis is a recognized high-yield direction for registry-based publications.

Hematologic Malignancies

Analysis of lymphomas (Hodgkin and non-Hodgkin), leukemias, plasma cell myeloma, and myeloproliferative disorders. These analyses require careful handling of histology coding, and our team applies validated recoding strategies to ensure cohort purity.

Special Populations

Focused studies on elderly patients (aged 65 and above), adolescent and young adult (AYA) populations, pediatric patients, and racial or ethnic subgroups. Special population research frequently reveals survival disparities and informs individualized treatment decisions.

Testing Items

We deliver a comprehensive portfolio of statistical analyses tailored to SEER data structures and the requirements of peer-reviewed oncology journals:

• Descriptive statistics and baseline demographic tables stratified by exposure or outcome variables
• Incidence and mortality trend analysis using Joinpoint regression, including annual percentage change (APC) and average annual percentage change (AAPC) with 95% confidence intervals
• Overall survival (OS) and cancer-specific survival (CSS) analysis using the Kaplan-Meier method with log-rank testing
• Univariate and multivariate Cox proportional hazards regression to identify independent prognostic factors
• Competing risk analysis using the Fine-Gray subdistribution hazard model to generate cumulative incidence curves
• Propensity score matching (PSM), inverse probability of treatment weighting (IPTW), and other causal inference techniques for treatment comparison studies
• Nomogram construction, internal validation, calibration curves, and decision curve analysis (DCA)
• Time-dependent receiver operating characteristic (ROC) analysis and area under the curve (AUC) estimation
• Subgroup analysis and interaction testing to assess effect modification
• Landmark analysis and conditional survival estimation for dynamic prognosis prediction

Testing Methods

All data extraction is performed using SEER*Stat software (version 8.4.x or later). Cohorts are defined according to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) topography and morphology codes, with diagnostic confirmation status, behavior recode, and sequence number applied as standard exclusion criteria. Patients with incomplete survival information or unknown follow-up are handled according to predefined statistical plans, and sensitivity analyses are performed when meaningful levels of missing data exist.

Statistical modeling is conducted primarily in R (version 4.0 or above) using established packages including survival, cmprsk, rms, riskRegression, and pec, with parallel verification available in SPSS and Stata upon request. The proportional hazards assumption is verified using Schoenfeld residual testing, and appropriate remedies such as time-varying coefficients or stratified models are applied when violations are detected. Categorical variables are converted according to clinically meaningful cut-points, while continuous variables such as age and tumor size are evaluated for non-linearity using restricted cubic splines. All analyses apply two-sided tests with a significance threshold of P less than 0.05.

Deliverables include cleaned datasets, fully commented analysis scripts, publication-quality figures generated to journal specifications (300 dpi, TIFF or EPS format), detailed statistical result tables, and methodological text suitable for direct insertion into the Materials and Methods section of a manuscript.

Applications

SEER experimental analysis supports a wide spectrum of research and clinical objectives:

• Prognostic factor research: identifying demographic, pathological, and treatment variables independently associated with patient survival to inform follow-up strategies.
• Clinical prediction models: developing and validating nomograms that estimate individualized survival probability and support shared clinical decision-making.
• Epidemiological surveillance: characterizing long-term trends in cancer incidence and mortality to guide public health resource allocation.
• Population-level treatment evaluation: comparing real-world outcomes of surgical approaches, radiotherapy utilization, and lymph node dissection strategies.
• Clinical stage system assessment: comparing the discriminatory ability of the 7th, 8th, and 9th editions of the AJCC staging systems for specific malignancies.
• Health disparity studies: quantifying survival differences across insurance status, income level, facility type, and race or ethnicity to inform equity-focused interventions.

FAQ

What is the turnaround time for a typical SEER analysis project?

Standard analysis projects are typically completed within 2 to 4 weeks, depending on cohort complexity and the number of statistical analyses required. Projects involving nomogram construction or multiple imputation of missing data may require additional time for model validation.

Do I need to apply for SEER data access separately?

Yes. SEER data access requires signing a SEER Research Data Agreement with the National Cancer Institute. The application is free of charge and is usually approved within several business days. Our team provides guidance on the application process and can perform all extraction work once access is granted.

Does SEER include detailed chemotherapy and targeted therapy information?

SEER records chemotherapy and immunotherapy as categorical variables (yes, no, or unknown) but does not specify drug names, regimens, or cycles. Radiotherapy records include beam energy and treatment location but not dose. Hormonal therapy and targeted agents are available only in limited years and registries. Study designs must account for these data granularity limitations, and our statisticians will advise on feasible endpoints during protocol development.

How is patient privacy protected in SEER research?

All SEER records are fully de-identified before release and contain no direct identifiers such as names, addresses, or exact dates. The database is certified as compliant with patient confidentiality requirements, and no institutional review board approval is typically required for publication using the public-use files.

Can the analysis results be used directly for journal submission?

Yes. All figures are produced to meet the technical requirements of major oncology journals, statistical tables follow standard reporting conventions, and we provide a completed statistical methods paragraph for your manuscript. We also offer revision support to address reviewer comments related to statistical methodology.